Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform FRACTYL HEALTH ANNOUNCES NOMINATION OF RJVA-001 AS FIRST CLINICAL CANDIDATE IN ITS REJUVA® GLP-1 GENE THERAPY PLATFORM

Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure Fractyl Health Announces New Pooled Analysis From Revita Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance without Gain

Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting Fractyl Health presented preclinical findings from its Rejuva® gene therapy platform at the WCIRD23 Annual Meeting.

Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...

Happy Bob Integrates With Dexcom CGM to Provide a Playful Way to Engage With Real-Time Glucose Values and Improve Overall Self-Care HELSINKI, March 08, 2022 (GLOBE NEWSWIRE) -- Diabetes tech startup Harald AI today introduced a more expansive way for Dexcom Continuous Glucose Monitoring (CGM) System users to engage with their...